Table 4.
Multivariate analysis of prognostic factors for OS and PFS.
| Factors | OS | PFS | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Pathology differentiation | 0.813 (0.609–1.085) | 0.160 | 0.896 (0.682–1.179) | 0.433 |
| Primary tumor site | 1.086 (0.521–2.263) | 0.826 | 0.676 (0.334–1.367) | 0.276 |
| Weight loss | 0.747 (0.561–0.994) | 0.046 | 1.107 (0.856–1.432) | 0.440 |
| Concurrent chemotherapy | 1.208 (0.892–1.637) | 0.221 | 1.405 (1.059–1.864) | 0.018 |
| T stage | 0.584 (0.371–0.920) | 0.020 | 0.635 (0.417–0.968) | 0.035 |
| Nstage | 0.743 (0.530–1.044) | 0.087 | 0.656 (0.480–0.896) | 0.008 |
| M stage | 0.801 (0.575–1.113) | 0.186 | 0.736 (0.538–1.008) | 0.056 |
| Clinical stage | 0.746 (0.444–1.253) | 0.268 | 0.563 (0.343–0.924) | 0.023 |
OS – overall survival; PFS – progression-free survival; HR – hazard ratio; 95% CI – 95% confidence interval.